Today, a group of 28 organizations, including ACI, sent a letter to the administrator of the Centers for Medicare and Medicaid Services (CMS) in opposition to proposed regulations that would demand additional rebates from drug prices, including drugs that may have applications for patients during the current COVID crisis. The letter explains the many unintended consequences that may result from the expansion of the CMS regulations, including — chilling drug innovation and investment; pushing costs to patients, insurers, and others; and discouraging the repurposing of existing drugs to fight COVID-19.

You can read the letter online at ACI.